Results 101 to 110 of about 3,108,169 (356)
FEBS Open Bio, EarlyView.Pharmacological inhibition of PERK in a DEN‐induced mouse model of liver cancer does not reduce tumor burden but alters cellular stress signaling. Despite blocking PERK activity, downstream stress responses, including CHOP expression, remain active, suggesting compensatory mechanisms within the unfolded protein response that may influence tumor ...
Ada Lerma‐Clavero +5 more
wiley +1 more source
Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy
Frontiers in Oncology, 2021 Melanoma is the most fatal skin cancer. In the early stages, it can be safely treated with surgery alone. However, since 2011, there has been an important revolution in the treatment of melanoma with new effective treatments.
Claudia Trojaniello +2 more
doaj +1 more source
A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon [PDF]
, 2012 Purpose: IFNa was the first cytokine to demonstrate anti-tumor activity in advanced melanoma. Despite the ability of high-dose IFNa reducing relapse and mortality by up to 33%, large majority of patients experience side effects and toxicity which ...
Alessandro Monaco +9 more
core +4 more sources
Shared Genetic Effects and Antagonistic Pleiotropy Between Multiple Sclerosis and Common Cancers
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Epidemiologic studies have reported inconsistent altered cancer risk in individuals with multiple sclerosis (MS). Factors such as immune dysregulation, comorbidities, and disease‐modifying therapies may contribute to this variability.
Asli Buyukkurt +5 more
wiley +1 more source
Secondary Adrenal Insufficiency in a Patient with Metastatic Melanoma Treated with Nivolumab
Case Reports in Dermatology, 2022 We report a case of secondary adrenal insufficiency due to nivolumab. An 83-year-old man with acral lentiginous types of melanoma on the right sole visited our department in March 2017.
Wataru Omata +8 more
doaj +1 more source
Approaches to decision-making among late-stage melanoma patients: a multifactorial investigation. [PDF]
, 2019 PurposeThe treatment decisions of melanoma patients are poorly understood. Most research on cancer patient decision-making focuses on limited components of specific treatment decisions.
Abramson, Corey M +3 more
core
Expression signatures of cisplatin- and trametinib-treated early-stage medaka melanomas [PDF]
, 2019 Small aquarium fish models provide useful systems not only for a better understanding of the molecular basis of many human diseases, but also for first-line screening to identify new drug candidates.
Boswell, William +7 more
core +2 more sources
Neoantigen Targetability in Progressive Advanced Melanoma
Clinical Cancer Research, 2023 Abstract Purpose: The availability of (neo)antigens and the infiltration of tumors by (neo)antigen-specific T cells are crucial factors in cancer immunotherapy. In this study, we aimed to investigate the targetability of (neo)antigens in advanced progessive melanoma and explore the potential ...
Jitske van den Bulk +17 more
openaire +3 more sources
Advanced Functional Materials, EarlyView.This study introduces VIVID (Vesicle In Vivo Identification using DNA), a qPCR‐based platform that tracks PCR‐amplifiable DNA tags loaded in the EVs for accurate and quantifiable EV biodistribution in vivo. ABSTRACT Extracellular vesicles (EVs) represent promising carriers for nucleic acid therapeutics, offering advantages over synthetic nanoparticles ...
Oscar Boyadjian +5 more
wiley +1 more source
The International Journal of Biological Markers, 2019 Purpose: With the recent developments in novel molecular targeted therapy such as immune-checkpoint blockades, serine/threonine-protein kinase B-Raf, and mitogen-activated protein kinase kinase inhibitors, the prognosis of advanced malignant melanoma has
Hiroshi Umemura +4 more
doaj +1 more source